

FY2024-2030 Medium-term Management Plan

VISION2030

April 17, 2024 FUJIFILM Holdings Corporation Update date : May 9th, 2024

Correction Page 44 Appendix-3 | VISION2030 : ROIC and Depreciation



Forward-looking statements, such as those relating to earnings forecasts and other projections contained in this material, are management's current assumptions and beliefs based on currently available information. Such forward-looking statements are subject to a number of risks, uncertainties, and other factors. Accordingly, actual results may differ materially from those projected due to various factors.

Fujifilm Group's Purpose

Giving our world more smiles

We bring diverse ideas, unique capabilities, and extraordinary people together to change the world.



FUJIFILM Agenda

01 Recap of Medium-term Management Plan "VISION2023"

New Medium-term Management Plan "VISION2030"

2-1 Overview

02

- 2-2 Towards a Sustainable Society
- 2-3 Portfolio Management
 - 2-4 Targets and KPI
 - 2-5 Financial Capital Strategy
 - 2-6 Strategy by Business

FUJIFILM Agenda

Recap of Medium-term Management Plan "VISION2023"

New Medium-term Management Plan "VISION2030"

2-1 Overview

01

02

- 2-2 Towards a Sustainable Society
- 2-3 Portfolio Management
 - 2-4 Targets and KPI
 - 2-5 Financial Capital Strategy
 - 2-6 Strategy by Business

FY2021-FY2023 Medium-term Management Plan

1-1 | Recap of VISION2023

- Achieved target of VISION2023 in Revenue and Operating income one year ahead of schedule. FY2023 is also expected to achieve a record high.
- □ KPIs for Capital Efficiency were not achieved, due to large capital expenditure in Bio-CDMO and Electronic Materials which were not in the original plan as well as ensuring enough inventory to prioritize stable supply under COVID-19.

			VISION2023					
		_			A	A-B	В	
		FY2020	FY2021	FY2022	FY2023		FY2023	
	(Billions of yen)	Actual	Actual	Actual	Forecast As of 2024/4/17	vs Original	Original plan As of 2021/4/15	
	Revenue	2,192.5	2,525.8	2,859.0	Record High 2,960.0	+9.6%	2,700.0	
		100%	100%	100%	100%		100	
Profitability	Operating Income	165.5	229.7	273.1	Record High 277.0	+6.5%	260.0	
		7.5%	9.1%	9.6%	9.4%	-0.2pt	9.69	
	Income before Income Taxes	235.9	260.4	282.2	Record High 310.0	+55.0%	200.0	
		10.8%	10.3%	9.9%	10.5%	+3.1pt	7.4	
	Net Income Arttribute to	181.2	211.2	219.4	Record High 240.0	+20.0%	200.0	
	FUJIFILM Holdings	8.3%	8.4%	7.7%	8.1%	+0.7pt	7.40	
	EPS	453.28yen	527.33yen	547.21yen	597.99 yen	+97.72yen	500.27ye	
Capital efficiency	ROE	8.7%	9.0%	8.3%	8.2%	-0.2pt	8.49	
	ROIC	4.3%	5.6%	6.1%	5.6 %	-0.5pt	6.1 9	
	CCC	123days	122days	125days	122 days	19days	103 day	
Financial soundness	Shareholders' equity ratio	62.1%	63.3%	66.8%	65.8%			
	D/E ratio	0.23	0.18	0.14	0.16			
Exchange(Average)	USD	106 yen	113 yen	136 yen	145 yen	+41 yen	104 уе	
	EUR	124 yen	131 yen	141 yen	157 yen	+33 yen	124 ye	

1-2 | Recap of VISION2023: By Segment

Achieved steady development in Healthcare and Electronic Materials and set Imaging on a growth path, while the challenge lies in improving resilience to volatility and enhancing profitability in each business field.

			A	A-B	В	
			FY2023		FY2023	
	(Billions of yen)		Forecast	vs Original	Original plan	
			As of 2024/4/17		As of 2021/4/15	
17	Healthcare	Revenue	975.0	+13.4%	860.0	 Medical Systems:Steady growth with IT and AI Bio-CDMO: Decision of investments for future growth.
		Operating Income	97.0	-5.8%	103.0	□ Challenge • Reinforcement of Small-scale manufacturing in Bio-CDMO, and Cell Culture media business in LS Solutions which are affected by biotech venture
	4	Operating Margin	9 .9%	-2.1pt	12.0%	funding stagnation.
1	Materials	Revenue	687.0	-4.6%	720.0	 ✓ Outcome Electronic Materials:Large M&As and aggressive investments Establishment of High Functional Materials Strategic HQ
		Operating Income	43.0	-54.7%	95.0	Challenge • Delayed recovery from COVID-19 impact (demand decrease in Graphics
	4	Operating Margin	6.3%	-6.9pt	13.2%	business, raw material price hikes, etc.)
	Business Innovation	Revenue	830.0	+1.2%	820.0	 Smooth transition to new company and structure Steady growth in Business Solutions (M&A, new services)
		Operating Income	71.0	-13.4%	82.0	Challenge • Maintain profitability of Office Solutions, which is experiencing a gradual decline in Print Volume
	4	Operating Margin	8.6%	-1.4pt	10.0%	Improve profitability of Business Solutions
	Imaging	Revenue	468.0	+56.0%	300.0	 Multiple Outcome Build on INSTAX's stable market base and dominant brand Two-line (X and GFX) strategy for digital cameras
		Operating Income	102.0	+4.1times	25.0	□ Challenge • Sustain silver halide photography (CLP and film)
		Operating Margin	21.8%	+13.5pt	8.3%	
l	Corporate Expenses	Revenue	-	-	-	
	& Eliminations	Operating Income	-36.0	+9.0	-45.0	
Т	Total	Revenue	2,960.0	+9.6%	2,700.0	
		Operating Income	277.0	+6.5%	260.0	
		Operating Margin	9.4%	-0.2pt	9.6%	
						FUJIFILM Holdings Corporation 6

1-3 | Recap of VISION2023: Sustainability (non-financial)

Toward sustainable growth and enhancement of corporate value over the medium to long term, We have worked to build a framework to continue to generate innovation and sources of value.

Environment	 Expect to reduce GHG emissions from own energy (Scope 1 + 2) by 11% (compared to FY 2019). Introduction of Internal Carbon Pricing (ICP) schemes. Recognized by CDP as an 'A-list company' for the second year in a row, the highest rating in the field of 'climate change'.
Human Resource	 Develop human talent that continues to create change by the concept of "STPD" and "+Story" Realization of a dynamic human resource portfolio through job rotation across businesses. Acceleration of diversity led by the "DE&I Promotion Office" and establishment of the "DE&I Committee" chaired by the CEO. *DE&I : Diversity, Equity & Inclusion
Corporate Governance	 Separation of the Board Chair and CEO for clarification of "supervisory" and "executive" roles on the Board. Ensure diversity on the Board (review of the skills matrix, increase in the number of female directors). Introduced "Restricted share-based remuneration" and "Medium-term performance-linked share-based remuneration" for Directors.
Diversity, Employee Satisfaction and Human Rights	 Establish a Group-wide DE&I vision. Implementation of measures to support work-family balance and establishment of health check-up facilities for employees. Revision of Guidelines for Global Healthcare Code of Conduct.
Co-creating value with stakeholders (Shareholders,Investors,Communit	 Organize business briefing hosted by the Company and participate in conferences hosted by securities firms. Strengthen timely, fair and impartial disclosure of information with simultaneous interpretation, transcripts, etc. Educational activities on tuberculosis screening, ICT to expedite issuance of disaster certificates.

FUJ!FILM Agenda

Recap of Medium-term Management Plan "VISION2023"

New Medium-term Management Plan "VISION2030"


- 2-1 Overview
- 2-2 Towards a Sustainable Society
- 2-3 Portfolio Management
 - 2-4 Targets and KPI
 - 2-5 Financial Capital Strategy
 - 2-6 Strategy by Business

New Medium-term Management Plan "VISION2030"

Overview

2-1-1 | What Should We Be in 2030

Enhance corporate value with focusing on Profitability and Capital Efficiency. As a collection of global top-tier businesses, we will change the world step-by-step and create value (more smiles) for various stakeholders.



2-1-2 | The Fujifilm Group's Approach to CSR

Sustainable Value Plan 2030 Under the SVP2030, the Fujifilm Group will contribute to realize a sustainable society by resolving social issues through innovative technologies, products, and services.



Sustainable Value Plan 2030 (SVP2030)


Long-term goal, which is expected to lay the foundations of the Group's business management strategies for sustainable growth.

2-1-3 | VISION2030 and our Group's Purpose



2-1-4 | Materiality and Direction of Our Efforts

We have set targets in each of four priority areas of the Environment, Health, Daily Life and Work Style, and are working to resolve social issues through our businesses.



New Medium-term Management Plan "VISION2030"

Towards a Sustainable Society

2-2-1 | Towards a Sustainable Society

With the belief that a commitment to the environment is a qualification for participation in global business, addressing issues in four areas in an integrated manner.



New Medium-term Management Plan "VISION2030"

Portfolio Management

2-3-1 | Policy of Portfolio Management

As a collection of global top-tier businesses, we will change the world step-by-step and create value (more smiles) for various stakeholders by strengthening the business portfolio management.

Business Portfolio Management


■ Healthcare ■ Electronics ■ Business Innovation ■ Imaging

High	N	ew /Future Potential	Growth Driver					
Market Attractiven	 Semiconductor 	Sciences (Cell and Gene Therapy) Materials (Advanced packaging) erials (Materials for Micro OLED, AR/VR)	Businesses • Medical Systems • Bio-CDMO/Life Sciences (Antiboo • Semiconductor Materials • Business Solutions (DX Solutions)					
ess (Gro	V	alue Reconstruction	Earnings Base					
owth Rate, etc	Value Reconstruction Businesses Graphic Communications Pharmaceuticals		 Businesses Display Materials Consumer Imaging 					
Ĭ	Definition Businesses that need to implement new strategies	Future Policies Restructure business strategy and implement measures	 Professional Imaging Office Solutions 					
Low		Strategy Planning Profitability o	f the company Shift to Earnings Base	► High				
S	Strategy for "Value Reconstruction" → Shift to "Earnings Base" • Graphic Communications -Integrated operation with Business Innovation -Increase in market share through promotion of processless printing materials -Focus on high-speed machine in digital printing area							
•	Pharmaceuticals	-Shift of focus areas: Drug discovery \rightarrow Drug discovery	support / Small molecule \rightarrow Biopharmaceuticals					
lf i	mprovement cannot be expected ev	en with the above measures, consider and implement new strate	gies, including reorganization and restructuring.	FUJIFILM Holdings Corporation 17				

2-3-2 | Reorganization of Segment

Reorganize "Graphic Communications" into Business Innovation segment.

This is to develop business as the only "Solution Partner" that can cover all areas from office to commercial and industrial printing.



* LS solutions:

Disclosure segment consisting of Life Sciences business (iPS cells, cell culture media, reagents), Pharmaceutical business, Consumer healthcare business (cosmetics, supplements), and CRO(Contracted Research Organization) business

New Medium-term Management Plan "VISION2030"

Targets and KPI

2-4-1 | Financial Target

Aggressive investment in Bio-CDMO and Semiconductor Materials in the three years to FY2026 will generate returns from FY2027 onwards, aiming for a company-wide operating margin of 15% in FY2030.

		FY2023	FY2024		FY2026		FY2030
	(Billions of yen)	Forecast		Change from		CAGR	
		As of 2024/4/17		FY2023		(FY2023→FY2026)	Direction
	Revenue	2,960.0	3,100.0	+4.7%	3,450.0	+5.2%	4 trillion yen
		100%	100%		100%		
Profitability	Operating Income	277.0	300.0	+8.3%	360.0	+9.1 %	ор м 15 %>
		9.4%	9.7%	+0.3pt	10.4%		
	Income before Income Taxes	310.0	310.0	-	360.0	+5.1%	
		10.5%	10.0%	-0.5pt	10.4%		
	Net Income Attributable to	240.0	240.0	-	270.0	+4.0%	
	FUJIFILM Holdings	8.1%	7.7%	-0.4pt	7.8%		
	EPS	199.33 _{yen}	199.33 yen	-	224.24 yen		
Capital efficiency	ROE	8.2%	7.8%	-0.4pt	8.1%		10%>
	ROIC	5.6%	5.4%	-0.2pt	5.8%		9%>
	CCC	122days	119 days	-3days	112 days		
Financial soundness	Shareholders' equity ratio	65.8%	61.9 %	-3.9pt	64.1 %		
	D/E ratio	0.16	0.28	+0.12	0.24		
Shareholder Returns	DPS	* 50yen	60yen	+10yen	DPR approx. 30 %		
Exchange(Average)	USD	145 yen	140 yen	-5 yen	140 yen		
	EUR	157 yen	150 yen	-7 yen	150 yen		

* One-for-three split of its common stocks was carried out on April 1, 2024. DPS for FY2023 is based on the number of shares issued converted to the value after stock split

		FY2023	FY2024		FY2026		FY2030
(Billions of yen)		Forecast As of 2024/4/17		Change from FY2023		CAGR (FY2023→FY2026)	Direction
Healthcare	Revenue	975.0	1,010.0	+3.6%	1,200.0	+7.2%	
	Operating Income	97.0	112.0	+15.5%	140.0	+13.0%	approx. 20 %
	Operating Margin	9.9%	11.1%	+1.2pt	11.7%		approx.20%
Electronics	Revenue	360.0	410.0	+13.9%	470.0	+9.3%	
	Operating Income	45.0	57.0	+26.7%	70.0	+15.9%	high 10 %s
	Operating Margin	12.5%	13.9%	+1.4pt	14.9%		nign 10%s
Business Innovation	Revenue	1,157.0	1,200.0	+3.7%	1,275.0	+3.3%	
	Operating Income	69.0	73.0	+5.8%	90.0	+9.3%	10%>
	Operating Margin	6.0%	6.1%	+0.1pt	7.1%		10%>
Imaging	Revenue	468.0	480.0	+2.6%	505.0	+2.6%	
	Operating Income	102.0	100.0	-2.0%	105.0	+1.0%	20%>
	Operating Margin	21.8%	20.8%	-1.0pt	20.8%		2070>
Corporate Expenses	Revenue	-	-	-	-	-	
& Eliminations	Operating Income	-36.0	-42.0	-6.0	-45.0	-	
Total	Revenue	2,960.0	3,100.0	+4.7%	3,450.0	+5.2%	
	Operating Income	277.0	300.0	+8.3%	360.0	+9.1%	
	Operating Margin	9.4%	9.7%	+0.3pt	10.4%		15 %>

* Graphic Communications business has been reclassified from the "Electronics" (Former "Materials") segment to the "Business Innovation" segment. In conjunction with this reclassification, information for FY2023 has been restated.

Enviro	nment		Health			
GHG emissions from our own energy, The entire product life compared to FY2019 GHG emissions, compared (FY2030) (FY2030)				Health Checkup Center NURA Number of locations opened (FY2030)		
50% reduction	50% reduc	ction	196 countries (FY2026 : 120 countries)	100 locations (FY2026: 30 locations)		
Work Style			Human capital			
A way of working that supports w to be more productive and crea (FY2030)		Percentage of women in managerial positions (FY2030)	Percentage of non-Japanese in key positions (FY2030)	Employee Engagement Survey Score of Sustainable Engagement*		
Provided to 50 million p (FY2026 : 35 million)	people	25%	35%	Maintain above 80% Incorporated into director's KPIs for ledium-term performance-linked equity remune		

* Surveyed as an indicator with a strong correlation to corporate performance. Defined at partner WTW (Willis Towers Watson)


FUJIFILM Holdings Corporation 22

New Medium-term Management Plan "VISION2030" Financial Capital Strategy

2-5-1 | Cash Allocation

 $1.9 \ {\rm trillion\ yen^*\ investment\ in\ growth\ over\ the\ next\ 3\ years,\ exceeding\ VISION2023}$ Out of this amount, $1.6 \ {\rm trillion\ yen\ will\ be\ allocated\ to\ "New\/Future\ Potential"\ and\ "Growth\ Driver"\ businesses}$

*Total R&D and capital expenditures to be invested in FY2024-FY2026



Additional large investment in Bio-CDMO and Semiconductor Materials to capture strong market demand Free Cash Flow will turn positive in FY2026 after heavy investment phase


¥1.08 trillion ¥1.35 trillion VISION2030 (FY2024→FY2026) **VISION2023 Capital Expenditure** w/tangible, Software, and rental equipment FY2021 FY2025 FY2022 FY2023 FY2024 FY2026 Free Cash Flow Healthcare Electronics Other

Capital Expenditure and Free Cash Flow Trends

* Graphic Communications business has been reclassified from the "Electronics" segment to the "Business Innovation" segment. In conjunction with this reclassification, numbers of FY2021-FY2023 has been restated.

2-5-3 | Shareholder Return Policy

The basic policy is to return profits to shareholders through dividends by balancing business growth and financial discipline. Buybacks will be considered and implemented based on the status of cash flow, share price, and other factors.



Shareholder Return Policy

- Maintain balance between business growth and financial discipline
- The basic policy is to return profits to shareholders through stable and continuous dividends.

Target payout ratio of 30%.

Share buybacks are considered and implemented based on the status of cash flow status, stock price and other factors.

Management that is conscious of Cost of Capital and Stock Price

2-5-4 | Implement Management That Is Conscious of Cost of Capital and Stock Price

By transforming the business portfolio and improving profitability and efficiency through previous medium-term plans, P/B (Price to book) Ratio raised to a stable level above 1.0x





Medical Systems

Long-term competitive environment & Major Risks

Shift to focusing on "prevention, early diagnosis, and early treatment" as a means of curbing the escalating medical expenditure
Increased need for operational efficiency in hospital management against a backdrop of physician shortages
Intensifying price competition in each product line due to the addition of emerging manufacturers to existing competitors

> Basic Strategies and Actions

- Wide range of equipment lineup and deepening of IT and AI technology to enhance our presence
- In addition to clinical value, create products and services that contribute to solving challenges in medical setting, such as providing workflow support
- Differentiation through solution proposals based on IT/AI and linkage with other equipment, rather than on stand-alone devices

• Expand recurring business leveraging IT and AI technology

• In the next three years, focus on accelerating IT implementation of various equipment and expand our market share, which will serve as earning base for our recurring business

• Acceleration of business in health checkup

- Expansion of existing business in health checkup
- Expand NURA, a health checkup center focusing on cancer screening, to 100 locations worldwide, mainly in emerging countries

Bio-CDMO

Long-term competitive environment & Major Risks

- As market of antibody drugs is growing (CAGR+8%), backed by strong investment by pharmaceutical companies, CDMO companies are required to have ample supply capacity and high productivity
- In addition to supply capacity, "track record" and "trust" are important to be selected for outsourcing in competitive environment
- Expanding needs for next-generation drugs (ADCs, bispecific antibodies, CGTx) and drug formulations with future growth potential

Basic Strategies and Actions

• "Partners for Life" Strategy

- Providing end-to-end services that support a wide range of pipelines from early development to commercial production
- Quick tech-transfer and respond to regulatory requirements and agility to meet fluctuating demand, backed by ample supply capacity
- Build track record and trust, and as a "Trusted Partner," deliver cutting-edge biopharmaceuticals to more patients more quickly and with reliable quality

Building and Optimizing production structure to meet growing demand

Large scale facilities:

- Additional investment in Holly Springs, North Carolina, U.S. (8 tanks: scheduled to start operation in 2028), one of the largest sites for antibody drugs in North America
- Expanding capacity by cloning existing highly productive facilities at a faster speed than other companies (KojoX)
- Small to Medium scale facilities:
 - Establishment of a production organization capable of meeting demand fluctuations (Restructuring, Conversion of facilities to antibody drugs)


• Development of next-generation technologies that will lead to sustainable growth

- Continuous Production System (continuous production of APIs from culture to purification):
 - Productivity improvement by applying N-1 Perfusion (20,000 L), Application of next-generation production technology (500-2,000 L)
- ADC (Antibody-Drug Conjugate):
 - Start of end-to-end CDMO service in Japan (Toyama), including antibody, conjugation, and drug formulation (scheduled for 2026)

2-6-1 | Healthcare – Bio-CDMO

Bio-CDMO

Aim to achieve 700 billion yen in revenue, with the contribution of new additional facilities in North Carolina, U.S., which will start operation in FY2028. Achieve stable and high profitability by increasing the rate of large tanks. Free cash flow of Bio-CDMO business is expected to turn positive in FY2027.



2-6-1 | Healthcare – Bio-CDMO

Bio-CDMO

Build an Earning Base (FY24-26) : Smoothly launch new large facilities. Structural reforms of small to mid- facilities in FY24 to rebuild the earnings base. Expand Profit (FY27-30) : Expand large scale tanks operations. Reap profits in line with demand recovery and the growth of new modalities for small to mid-facilities.

			Build an Earning Base (FY24-26)	Expand Profit (FY27-FY30)	Ilustration of EBITDA Margin Trends
	Modality	Market	Stra	tegy	*excludes one-time expense (e.g., inventory write-downs in FY23 and reforming cost in FY24)
Large Scale	Antibody drugs (mAb) (≥20,000ℓ)	Strong demand continues • Outsourcing to CDMO is increasing. • Launch of new pipelines.	Smooth Launch of new facilities	Expand productivity of new facilities Launch of new facilities in U.S. (20,000 L x 8 tanks)	Large Scale Approx. 40% 20% range
	Antibody drugs (mAb) (≦5,000ℓ)		Optimization to meet fluctuating demand	Expand earnings in line with market expansion and regrowth	Total Mid Teens
Small to Mid- Scale	Recombinant Protein		 Cost reduction by restructuring Conversion of tank 	Capacity expansion to meet clinical and early-stage demand	No.
	Gene Therapeutics (GT)	Stagnation caused by biotech funding issue is expected be	 (GT to mAb) Reinforcement of commercial Production (Additional 5KL tanks in UK) 	End to End ADC sonvice	Small to Mid- Scale Upfront cost for new facilities Reap profit centered on Large Scale tanks
1 <u>4</u>	Cellular	fully recovered in the late	laure stars and feed to a m	Production Technology	FY22 FY23 FY24 FY25 FY26 FY27 FY30
	Therapeutics (CT)	2020s.	Investment for long- term market growth	Improve profit by acquiring new customers	Build an Expand Earning Base Profit
					FUJIFILM Holdings Corporation 32

Life Science

Long-term competitive environment & Major Risks

- Driven by high-growth biopharmaceutical demand, materials for drug discovery support and drug manufacturing also continue to grow
- Differentiation and gaining a competitive advantage by providing solutions combining iPS cells, cell culture media, and reagents and by developing distinctive products
- Intensifying competition in cell culture media for antibody drug production as purchasing from multi-supplier is increasing

> Basic Strategies and Actions

- "Partners for Life" Strategy
- Create solutions that contribute to drug discovery, drug manufacturing, and healthcare with iPS cells, culture media, and reagents
- Become a "Trusted Partner" by pursuing satisfaction of a broad customers including pharmaceutical companies, biotech, and academia

• iPS cells : Supporting the cell therapy drug pipeline from the discovery and research stage

• Earn milestone royalty income in line with the progress of development by providing and licensing iPS cell lines, while simultaneously build up iPS cells CDMO business with accumulating a track record through contracted development

• Cell Culture media: Stabilize product supply by expanding production sites and strengthening supply chain

- Growth and profitability improvement through timely capital expenditure to increase production capacity, especially for antibody drug
- Expand production site in areas closer to customers to achieve stable supply along with a stronger supply chain structure

• Drug Discovery Support Materials: Focus on next-generation modalities

• Strengthen product development and customer service for next-generation cell and gene therapies

Semiconductor Materials

Long-term competitive environment & Major Risks

- Market growth for semiconductors supporting DX/AI technology will continue at a CAGR of +7% from 2023 onward
- In addition to miniaturization, technology evolution in the back-end process for integrating multiple chips is accelerating
- Increased geopolitical risks in terms of economic security

Basic Strategies and Actions

- Strengthening the supply chain network for global customers and winning business in advanced nodes
- Aggressive investment in response to expansion by major semiconductor manufacturers in the U.S., Europe, and Asia
- Expanding business through one-stop solutions, as well as acquiring business with advanced EUV based on our strengths in CMP slurries and NTI developer solutions, which have a high market share, and introduce new materials for Beyond EUV lithography
- Execution of PMI for the process chemical business acquired in 2023 and leverage connections with customers in our existing materials

• Responding to geopolitical risks and launching/expanding business in emerging markets


- Supply chain networking considering geopolitical risks
- Early entry and business development into emerging markets


• Develop high value-added products by leveraging our broad portfolio and technologies

- Launch of back-end material products and businesses utilizing front-end material technology
- Accelerate development of new materials and technologies for image sensors

2-6-2 | Electronics - Semiconductor Materials

Semiconductor Materials





Become the world's most trusted partner in semiconductor materials

Display Materials and Other Electronics Materials

Long-term competitive environment & Major Risks

- Materials are required to support the explosion of communication volume and changes in energy infrastructure, in addition to the development of Human Machine Interface (HMI) which connect the real world and cyber space
- The ability to foresee changes in the market and technology, and to promptly and consistently propose new materials that address social problems, is considered important.

Basic Strategies and Actions

Propose new materials that meet customer needs by reorganizing department to be more market-oriented

• Addressing the Development of Human Machine Interface (HMI)

- Promoting business in growth markets such as anti-reflective materials for OLED, which is expanding in smartphones and IT, touchsensor materials and light-emitting layer materials
- Increase presence in the industry by proposing new materials (e.g. Materials for High-definition color filters, Thin-layer optical films, Reflective films for head-up displays) to manufactures for micro-OLED, AR/VR and mobility, which are expected to be the next generation HMI, and assist them in problem-solving

New businesses in Telecommunications and Energy market

 Based on core technologies such as Flow synthesis, High-purity liquefaction, Optical control using liquid crystals, etc., we propose to develop and implement new materials (e.g. Materials for separation and recovery of rare metal*) using our customer base that we have cultivated in the telecommunications (e.g. Data center archives) and energy business areas

Business Innovation

Long-term competitive environment & Major Risks

- Print volumes on MFPs and printers are downwards due to digitization and hybrid work, although decline in A3 color is moderate due to replacement from monochrome *MFP : Multifunction Printer
- While the need for DX is increasing, SME customers are facing challenges due to a lack of resources, resulting in a delay in achieving DX
- In commercial printing, demand for large-volume (analog) printing, monochrome printing, etc. will decline, while demand for high-mix, small-lot (digital) printing and color printing will increase, leading to greater needs for high-speed digital printing and DX. Also demands for commercial printing, such as heads for inkjet printers for package printing (flexible packaging, labels, etc.), and water-based pigment inks and colorants for food safety are increasing

> Basic Strategies and Actions

- Become a solution partner supporting the digital shift of every customer, starting with the best devices for the environment and sustainable customer service
 - Managed as a "Printing & Solutions" business through integration of Graphic Communications into Business Innovation, as the only solution provider covering all areas from office to commercial (analog and digital) and industrial printing
 - For customers in a wide range of fields including office, commercial, and industrial printing, we offer a lineup of xerography and inkjet technologies, as well as device and DX solutions based on the synergy and our ability to solve challenges in customers
 - Improve profitability of Graphic Communication and shift its position in the portfolio from "Value reconstruction" to "Earning base", by leveraging our strong domestic market share and customer base, enhancing cash generation of Analog printing business which have lean structure by streamlined global production line, and investing in digitalization for commercial printing
 - Build business alliance with external partner to further strengthen business foundation by integrating procurement function of raw materials and components, and building toner development and production supply systems

Leveraging further group synergies

- Sales synergies through mutual utilization of channels and customer bases by integrating BI and GC
- Strengthen competitiveness through integrated development by bringing together the technologies and know-how of BI and GC
- Expand sales of digital printing presses for the photo industry through joint development with Imaging

* BI : Business Innovation , GC: Graphic Communications

FUJIFILM Holdings Corporation 38

2-6-3 | Business Innovation

Business Strategies

- > Business Solutions
- While growth in "IT/Business solutions" centered on new in-house solutions (IT Expert Services, FUJIFILM IWpro, etc.) for SMEs, expand the "ERP solutions" based on D365 to acquire a new earning base
- Provide new value to customers, by supporting business optimization based on the data accumulated through each solutions

> Office Solutions

• Focus on A3 color segment with top-level market share. Maintain and improve revenue

and operating income with prioritizing environmental friendliness, reinforcement of production base, and sales productivity


• Commencement of new distribution channel of our MFP by leading distributors in Europe

> Graphic Communications

- In response to the decline in demand for analog printing, already streamlined the production lines for plate materials. Improve profitability by concentrating on expanding sales of the high value-added Processless Plate*
- Investment in digital printing/DX for the growing market of commercial printing, and provision of device and DX solutions to support the digital shift from analog to digital printing for analog plate customers
- Build an earning base and generate further cash through revision of sales price and restructuring of low-profit products

*Processless Plate:

No development process is required, which reduces workload and costs, and is environmentally friendly (no developer solution is used and no waste liquid is produced).



2-6-4 | Imaging

Imaging

Long-term competitive environment & Major Risks

- Diversification of photographic and visual expressions, products and solutions due to technological progress, changes in the social environment and changes in user awareness and behavior
- Increased demand for realistic communication, analogue sensibilities, surprises and overwhelming emotions that resonate with the natural human sensibility
 - Possible Changes | CPS (Cyber Physical System) penetration, Ultrafast and Multiple-connected network society, AR/VR becoming a tool for daily life, Image generation through AI, Evolution and diversification of imaging devices, Fusion of photo and printing

> Basic Strategies and Actions

• Growth of INSTAX/ Digital Cameras as a revenue driver

- INSTAX: Promote the use of devices and services, and encourage users to print films
- Expand the customer base by continuously launching attractive and unique products that combine analog taste with digital technology
- Capture demand at events and in BtoB space
- Increase loyal customers by marketing DX and enforcing direct user communication
- Digital Cameras: Increasing market presence by establishing a unique position
- Reinforces the two-line strategy of the compact, lightweight "X Series" and the large-format, highest image quality "GFX Series"
- Expand user base with our unique color imaging technology (film simulation) and wider coverage of photography categories and image expressions

• Expand growth in new BtoB areas

- Create new businesses and solve social issues by combining technological assets, unique devices, and expertise in imaging
- Market expansion of new products ("Z projector for space production," "Long range surveillance cameras SX series") using our imaging and optical device technology
- Solving social issues through "DX solutions for business-use (inspection, surveillance, photography, etc.) using AI image analysis and synthesis"

MORE**SMILES**

Innovation is what we do. Smiles are why we do it.



New Medium-term Management Plan "VISION2030" Appendix

Revenue by Business

	FY2022 Actual	FY2023 Previous forecast (As of 2024/2/8)	FY2023 Revised forecast (As of 2024/4/17)	Change f previous		Change f previous fo	
Healthcare	928.6	970.0	975.0	46.4	+5.0%	5.0	+0.5%
Medical Systems	621.8	650.0	660.0	38.2	+6.1%	10.0	+1.5%
Bio CDMO	194.2	195.0	200.0	5.8	+3.0%	5.0	+2.6%
LS Solutions	112.6	125.0	115.0	2.4	+2.1%	-10.0	-8.0%
Materials	682.0	687.0	687.0	5.0	+0.7%	-	-
Electronics	180.6	195.0	200.0	19.4	+10.7%	5.0	+2.6%
Display Materials	70.1	75.0	75.0	4.9	+7.0%	-	-
Other Advanced Materials	89.3	90.0	85.0	-4.3	-4.8%	-5.0	-5.6%
Graphic Communication	342.0	327.0	327.0	-15.0	-4.4%	-	-
Business Innovation	838.1	830.0	830.0	-8.1	-1.0%	-	-
Office Solutions	555.5	535.0	530.0	-25.5	-4.6%	-5.0	-0.9%
Business Solutions	282.6	295.0	300.0	17.4	+6.2%	5.0	+1.7%
Imaging	410.3	463.0	468.0	57.7	+14.1%	5.0	+1.1%
Consumer Imaging	266.9	298.0	298.0	31.1	+11.7%	-	-
Professional Imaging	143.4	165.0	170.0	26.6	+18.5%	5.0	+3.0%
Total	2,859.0	2,950.0	2,960.0	101.0	+3.5%	10.0	0.3%
Exhange Rates							
USD	136 yen	144 yen	145 yen	+9 yen		+1 yen	
EUR	141 yen	155 yen	157 yen	+16 yen		+2 yen	

FUJIFILM Holdings Corporation 42

(Billions of yen)

by Business					(Billions of y
	FY2023 Revised forecast (As of 2024/4/17)	FY2024 VISION2030	Change previous		FY2026 VISION2030
Healthcare	975.0	1,010.0	35.0	+3.6%	1,200
Medical Systems	660.0	670.0	10.0	+1.5%	71
Bio CDMO	200.0	215.0	15.0	+7.5%	35
LS Solutions	115.0	125.0	10.0	+8.7%	13
Electronics	360.0	410.0	50.0	+13.9%	47(
Semiconductor Materials	200.0	240.0	40.0	+20.0%	30
Display Materials	75.0	83.0	8.0	+10.7%	g
Other Electronics Materials	85.0	87.0	2.0	+2.3%	8
Business Innovation	1,157.0	1,200.0	43.0	+3.7%	1,27
Business Solutions	300.0	330.0	30.0	+10.0%	38
Office Solutions	530.0	530.0	-	-	52
Graphic Communication	327.0	340.0	13.0	+4.0%	37
Imaging	468.0	480.0	12.0	+2.6%	50
Consumer Imaging	298.0	295.0	-3.0	-1.0%	31
Professional Imaging	170.0	185.0	15.0	+8.7%	19
Total	2,960.0	3,100.0	140.0	+4.7%	3,45
Exhange Rates					
USD	145 yen	140 yen	-5 yen		140
EUR	157 yen	150 yen	-7 yen		150

Revenue by Business

* Graphic Communications business has been reclassified from the "Electronics" segment to the "Business Innovation" segment. In conjunction with this reclassification, information for FY2023 has been restated.

ROIC

			(Billions of Yen)
	FY2023 Revised forecast (As of 2024/4/17)	FY2024 VISION2030	FY2026 VISION2030
Healthcare	3.6%	3.7%	4.1%
Electronics	7.0%	8.2%	9.3%
Business Innovation	4.8%	5.0%	6.7%
Imaging	40.8%	39.3%	37.2%
*ROIC per segment = NOPAT/(Working capital	+ Fixed assets)		
Total	5.6%	5.4%	5.8%

*Group-wide ROIC = NOPAT/(Interest-bearing debt + Shareholder's equity)

Depreciation
The figures of Business Innovation for the fiscal years ending March 2025 and March 2027, which were announced on April 17, have been revised from "54.0 billion yen" and "66.0 billion yen" respectively. As a result, the total amounts of the entire company for the subject periods have been revised from "173.0 billion yen" and "243.0 billion yen".
(Billions of Yen)

	FY2023 Revised forecast (As of 2024/4/17)	FY2024 VISION2030	FY2026 VISION2030
Healthcare	57.0	63.0	108.0
Electronics	26.0	33.0	41.0
Business Innovation	49.0	51.0 🤣	55.0 🤇
Imaging	14.0	17.0	21.0
Corporate Expenses & Eliminations	5.0	6.0	7.0
Total	151.0	170.0 🥝	232.0 <

* Graphic Communications business has been reclassified from the "Electronics" segment to the "Business Innovation" segment. In conjunction with this reclassification, information for FY2023 has been restated.

Capital Expenditure and R&D Expense (FY2024~FY2026)

			(Billions of yen)
	Capital expenditure	R&D expenses	Total
Healthcare	863.0	186.0	1,049.0
Electronics	180.0	97.0	277.0
Business Innovation	198.0	164.0	362.0
Imaging	81.0	42.0	123.0
Corporate Expenses & Eliminations	28.0	31.0	59.0
Total	1,350.0	520.0	1,870.0

